Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section (RocSugIO)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The project aims to introduce into clinical practice for Caesarean section conducted under general anesthesia with the rapid induction myorelaxation with rocuronium and the reversal of neuromuscular blockade by using sugammadex. The aim is to demonstrate at least the same efficiency and confirm the safety of the procedure for both mother and newborn compared with older procedure.
| Condition | Intervention | Phase |
|---|---|---|
|
Caesarean Section Pregnancy |
Drug: Rocuronium + sugammadex Drug: Succinylcholine + Neostigmine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Factorial Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section |
- time needed to tracheal intubation [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]Quality: Rapid induction to general anesthesia with administration propofol and rocuronium for termination the pregnancy by Caesarean section are at least as good as the combination of propofol and succinylcholine iodide.Recording and evaluated will be the time from the beginning as the first drug in the rapid induction to general anesthesia will be administered until the discovery of the first wave of etCO2 after successful intubation (seconds), evaluation of intubation conditions (resistance to laryngoscopy, position of the vocal cords, response to the intubation attempt (limbs movement or cough) scored 1-3 according to level terms, conditions, entry scores for direct visualization of the vocal cords by Cormack-Lehane (I-IV)
- total procedure time [ Time Frame: 2 years ] [ Designated as safety issue: No ]Economics: After reversal of neuromuscular blockade using sugammadex are procedure time and turnovers shorter than the use of neostigmine in the recommended dosage for patients undergoing termination of pregnancy by Caesarean section. Recording and evaluated will be the total procedure time until the recovery from neuromuscular blockade to the level of TOF ratio of 0.9, the administration of the recovery dose will in group ROCSUG in the case for posttetanic count mode in the level of PTC1, 2 at a dose of sugammadex 4mg/kg , the TOF count 1.2 sugammadex at a dose of 2 mg / kg, in the case of failure to achieve these values the anesthesiologist wil wait with the administration of the recovery dose for their achievement. In group SUCNEO for achieving TOF count 1.2 and higher, the dose of atropine to 0.01 mg / kg and neostigmine 0.03 mg / kg will be administered.
- complications during anesthesia and during perioperation period [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]Rocuronium, sugammadex doesn´t lead to the deterioration of perinatal parameters and leads to fewer complications during anesthesia and postoperative period against a combination of succinylcholine iodide, rocuronium and neostigmine.Demographic characteristics (age,weight,BMI,gain in pregnancy,previous pregnancy, complications during pregnancy,medication during pregnancy), multiple gestation,parity,fetal position,the reason for the indication of caesarean section, the reason for general anesthesia caesarean section,week of termination of pregnancy,fetal weight,umbilical cord blood pH, pCO2,pO2,BE,Apgar,sex of the fetus,STAN or CTG assessment,the nature of amniotic fluid,time to cutting the umbilical cord will be monitored. Anesthesia complications (present or absent),the evaluation questionnaire of subjective feelings of the patient 1 day after caesarean section - sore throat,vigilance during anesthesia,myalgia,diplopia,weakness,inability to cough,shortness of breath will be recorded
| Estimated Enrollment: | 240 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | January 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Rocuronium + sugammadex
Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
|
Drug: Rocuronium + sugammadex
Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
|
|
Experimental: Succinylcholine + Neostigmine
Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
|
Drug: Succinylcholine + Neostigmine
1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
|
Detailed Description:
Project "Modern myorelaxation procedure and reversal of neuromuscular blockade during general anesthesia for caesarean section" aims to introduce in other indications for rapid induction of general anesthesia common and safe, alternative method of combining short-acting intravenous anesthetics propofol and fast-onset non-depolarizing muscle relaxant rocuronium into the clinical practice and demonstrate the efficacy and safety in this indication. At the same time to demonstrate the benefits of using modern reversal of neuromuscular blockade by sugammadex in termination the caesarean section under general anesthesia. Both procedures will be monitored by clinical observation, monitoring instrumentation and laboratory examination of mother and fetus (newborn) in various stages of peripartal period. The main benefit of this procedure will be in particular risk groups of mothers which are indicated by Caesarean Section while neuraxial blockade is contraindicated.
Eligibility| Ages Eligible for Study: | 14 Years to 60 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- caesarian section under general anesthesia in informed patient (after interview with anesthesiologist and obtain the signature for informed consent)
Exclusion Criteria:
- patient disagreement
- indicated and performed neuraxial blockade
- the anesthesiologist or obstetrician opposition to their inclusion in the study
- allergy or intolerance to one or more of study drug or known allergies or reactions to iodine
Contacts and Locations| Contact: Petr Štourač, MD | +420 602 745 841 | petr.stourac@gmail.com |
| Contact: Jozef Klučka, MD | +420776187053 | jozefklucka@seznam.cz |
| Czech Republic | |
| Faculty hospital Brno | Recruiting |
| Brno, Jihomoravský Kraj, Czech Republic, 62500 | |
| Contact: Petr Štourač, MD +420 602 745 841 petr.stourac@gmail.com | |
| Sub-Investigator: Jozef Klučka, MD | |
| Sub-Investigator: Roman Štoudek, MD | |
| Sub-Investigator: Ivo Křikava, MD | |
| Sub-Investigator: Petr Janků, MD, Ph.D | |
| Sub-Investigator: Ivana Bártíková, MD | |
| Sub-Investigator: Zuzana Hodická, MD, Ph.D | |
| Sub-Investigator: Pavel Ševčík, Prof.MD.CSc. | |
| Sub-Investigator: Dagmar Seidlová, MD, Ph.D | |
| Principal Investigator: Petr Štourač, MD | |
| Faculty Hospital Olomouc | Recruiting |
| Olomouc, Olomoucký kraj, Czech Republic, 775 20 | |
| Contact: Milan Adamus, Doc.MD.CSc. Milan.Adamus@akutne.cz | |
| Sub-Investigator: Martina Kirchnerová, MD | |
| Sub-Investigator: Jana Frančáková, MD | |
| Sub-Investigator: Lenka Obare Pyszková, MD | |
| Sub-Investigator: Zdeněk Mrozek, MD, Ph.D | |
| Sub-Investigator: Jarmila Hložková, MD | |
| Principal Investigator: Milan Adamus, Doc.MD.CSc. | |
| Study Director: | Petr Štourač, MD | Brno Faculty hospital, department of anesthesiology and intensive care medicine |
More Information
Additional Information:
No publications provided
| Responsible Party: | Petr Štourač, MD, MD, Faculty hospital Brno |
| ClinicalTrials.gov Identifier: | NCT01718236 History of Changes |
| Other Study ID Numbers: | IGA NT 13906-4 |
| Study First Received: | October 24, 2012 |
| Last Updated: | December 17, 2012 |
| Health Authority: | Czech Republic: State Institute for Drug Control |
Keywords provided by Brno University Hospital:
|
caesarean section rocuronium sugammadex |
Additional relevant MeSH terms:
|
Anesthetics Succinylcholine Rocuronium Neostigmine Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Neuromuscular Depolarizing Agents Neuromuscular Blocking Agents |
Neuromuscular Agents Peripheral Nervous System Agents Cholinesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Parasympathomimetics Autonomic Agents Neuromuscular Nondepolarizing Agents |
ClinicalTrials.gov processed this record on May 22, 2013